These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9630847)
1. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry. Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847 [TBL] [Abstract][Full Text] [Related]
2. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816 [TBL] [Abstract][Full Text] [Related]
4. Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Sava G; Pacor S; Bergamo A; Cocchietto M; Mestroni G; Alessio E Chem Biol Interact; 1995 Mar; 95(1-2):109-26. PubMed ID: 7697744 [TBL] [Abstract][Full Text] [Related]
5. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556 [TBL] [Abstract][Full Text] [Related]
6. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. Sava G; Capozzi I; Bergamo A; Gagliardi R; Cocchietto M; Masiero L; Onisto M; Alessio E; Mestroni G; Garbisa S Int J Cancer; 1996 Sep; 68(1):60-6. PubMed ID: 8895542 [TBL] [Abstract][Full Text] [Related]
7. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891 [TBL] [Abstract][Full Text] [Related]
9. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754 [TBL] [Abstract][Full Text] [Related]
11. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985 [TBL] [Abstract][Full Text] [Related]
12. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors. Sava G; Pacor S; Mestroni G; Alessio E Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212 [TBL] [Abstract][Full Text] [Related]
13. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425 [TBL] [Abstract][Full Text] [Related]
14. Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Sava G; Pacor S; Mestroni G; Alessio E Clin Exp Metastasis; 1992 Jul; 10(4):273-80. PubMed ID: 1617835 [TBL] [Abstract][Full Text] [Related]
15. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells. Bacac M; Vadori M; Sava G; Pacor S Cancer Immunol Immunother; 2004 Dec; 53(12):1101-10. PubMed ID: 15221285 [TBL] [Abstract][Full Text] [Related]
16. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322 [TBL] [Abstract][Full Text] [Related]
17. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells. Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274 [TBL] [Abstract][Full Text] [Related]
18. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748 [TBL] [Abstract][Full Text] [Related]
19. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599 [TBL] [Abstract][Full Text] [Related]
20. Isolation of a murine metastatic cell line and preliminary test of sensitivity to the anti-metastasis agent NAMI-A. Pacor S; Vadori M; Vita F; Bacac M; Soranzo MR; Zabucchi G; Sava G Anticancer Res; 2001; 21(4A):2523-30. PubMed ID: 11724317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]